Truqap®
capivasertib
160 mg • 200 mg tablets

Blister packs are now available

Helps track 4 consecutive days on treatment every week

Supports medication tracking

Blister packs provide a clear, visual dosage history, which simplifies medication tracking during the 4 consecutive days on treatment, helping patients to follow their dosing schedule more easily.



With each TRUQAP blister pack prescription, your patient will receive 4 child-resistant blister packs—1 for each week of the month.

They are designed with easy-to-use instructions to help support medication tracking.

Travel-friendly packaging

MM/DD

Customizable start date on the front for easy, weekly tracking

AM/PM-labeled and color-coded dosing cues

Please see Important Product Information on back, and accompanying full Prescribing Information, including Patient Information for TRUQAP.

Start your patients on TRUQAP blister packs

Truqap®
capivasertib
160 mg • 200 mg tablets

Learn more about the dosing schedule for TRUQAP

The following dosages are now available in blister packs:

400 mg twice daily[1]
Starting dose



Two 200-mg tablets BID

NDC 0310-9501-02

320 mg twice daily[1]
First dose reduction due to ARs



Two 160-mg tablets BID

NDC 0310-9500-02

- Bottles of 200-mg tablets will still be available for dispensing the 200-mg BID dose
- The 160-mg prescription bottle will be retired by the end of 2024

If you have further inquiries about how to prescribe TRUQAP blister packs, please contact your pharmacist.

AR=adverse reaction.

SELECT SAFETY INFORMATION ABOUT TRUQAP® (capivasertib) tablets

TRUQAP is contraindicated in patients with severe hypersensitivity to TRUQAP or any of its components.

Serious adverse reactions can include hyperglycemia, diarrhea, and cutaneous adverse reactions. May cause fetal harm when administered to a pregnant woman. Among the 355 patients who received TRUQAP in CAPItello-291, the most common (≥20%) adverse reactions, including laboratory abnormalities, were diarrhea (72%), cutaneous adverse reactions (58%), increased random glucose (57%), decreased lymphocytes (47%), decreased hemoglobin (45%), nausea and fatigue (35% each), increased fasting glucose (37%), decreased leukocytes (32%), increased triglycerides (27%), decreased neutrophils (23%), increased creatinine (22%), vomiting (21%), and stomatitis (20%).

INDICATION AND USAGE

TRUQAP in combination with fulvestrant is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more *PIK3CA/AKT1/PTEN* alteration as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

Please see accompanying full Prescribing Information, including Patient Information for TRUQAP.

You are encouraged to report negative side effects of AstraZeneca prescription drugs by calling 1-800-236-9933. If you prefer to report these to the FDA, call 1-800-FDA-1088.

Reference: 1. TRUQAP® (capivasertib) tablets [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.

AstraZeneca